{"id":"NCT01184846","sponsor":"CSL Behring","briefTitle":"Study of Efficacy and Safety of Privigen in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy","officialTitle":"A Single-arm Study to Demonstrate the Efficacy and Safety of Privigen in the Treatment of Subjects With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-11","primaryCompletion":"2011-11","completion":"2011-11","firstPosted":"2010-08-19","resultsPosted":"2013-04-04","lastUpdate":"2024-06-25"},"enrollment":31,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Inflammatory Demyelinating Polyneuropathy"],"interventions":[{"type":"BIOLOGICAL","name":"10% liquid formulation of human immunoglobulin","otherNames":["IgPro10; Privigen"]}],"arms":[{"label":"IgPro10","type":"EXPERIMENTAL"}],"summary":"The objective of this study is to demonstrate the efficacy and safety of Privigen in subjects with CIDP.","primaryOutcome":{"measure":"Responder Rate","timeFrame":"25 weeks","effectByArm":[{"arm":"IgPro10","deltaMin":60.7,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":10,"exclusionCount":22},"locations":{"siteCount":22,"countries":["Belgium","Finland","France","Germany","Poland"]},"refs":{"pmids":["23781960","28594116"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":28},"commonTop":["Headache","Pain in extremity","Leukopenia","Asthenia","Hypertension"]}}